Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,123 total articles
On January 21, 2026, Entegris Inc. Senior Vice President Clinton M. Haris sold 5,830 shares of the company at $120 per share, totaling nearly $700,000. Concurrently, Haris exercised options to acquire 5,830 shares at $55.72 each. Following these transactions, Haris holds over 37,700 shares of Entegris. The company also declared a quarterly cash div…
Andrew J. Quigg, Chief Strategy Officer of Progressive Corp, sold 1,649 shares worth approximately $337,000 under a structured trading plan. The insurer recently introduced a pet insurance offering across numerous U.S. states. Analyst opinions on Progressive vary, with some upgrades balanced by lowered price targets reflecting regional rate challen…
Oragenics Inc experienced a director-led transaction involving the sale of a modest number of shares alongside the acquisition of a substantial quantity of stock options. While the company's stock has suffered a pronounced decrease over the past year, financial metrics indicate a solid liquidity position. Investors may find current valuations intri…
Jonathan S. Bauer, Chief Investment Officer of Progressive Corporation, sold over 3,000 shares in January under a pre-arranged trading plan. Concurrently, Progressive Insurance debuted a pet insurance product across 43 states and the District of Columbia. Analyst opinions on Progressive's outlook show divergence, with Barclays upgrading shares base…
Saba Capital Management, holding a substantial stake in BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT), executed the sale of 272,613 shares across two days, yielding approximately $4.19 million in proceeds. These transactions marginally lowered the firm's ownership in ECAT amidst the trust's robust dividend payout and stable market perf…
Murray Stahl, who serves as the President and Co-Portfolio Manager of RENN Fund, Inc., recently augmented his holdings by acquiring an additional 1,134 shares in the company. This transaction valued at just over $3,000 underscores Stahl's personal commitment to the fund, which boasts a favorable valuation and robust profitability with a current mar…
Guidewire Software's CEO, Michael George Rosenbaum, sold 1,200 shares of the company's stock at $156.26 per share, totaling $187,512. This transaction was carried out under a 10b5-1 trading plan. Concurrently, Guidewire has initiated a new $500 million share repurchase program following the completion of its prior buyback authorization. Investor se…
Commercial Metals Company director Dennis V. Arriola has increased his stake in the company by acquiring 2,000 shares at $74.69 each, totaling $149,380. This move comes as the company reported first-quarter fiscal 2026 results that surpassed analyst expectations on both earnings and revenue. Subsequently, Jefferies raised its price target for the s…
RenovoRx's Chief Medical Officer, Ramtin Agah, recently expanded his equity position by purchasing 10,000 shares at an average price just below $1 per share. This insider buying comes on the heels of the company's third-quarter 2025 financial report, which revealed revenues that missed analyst projections, though earnings per share aligned with mar…
Julie Andrews, CFO of Orthofix Medical Inc., has recently sold nearly 4,900 shares of the company’s stock valued at over $70,000 to cover tax obligations linked to restricted stock units. The transaction was mandated by the Compensation and Talent Development Committee with no personal discretion from Andrews. Concurrently, Orthofix reported its th…
Julie Andrews, CFO of Orthofix Medical Inc., divested 4,873 shares of the company's stock to fulfill tax withholding requirements stemming from restricted stock units. The sale, which was not at Andrews' discretion but mandated by the board committee, comes amid the firm's recent reporting of mixed third-quarter financial outcomes, with earnings pe…
Cedric Francois, CEO of Apellis Pharmaceuticals, executed a stock sale on January 20, 2026, liquidating over 8,000 shares to raise approximately $162,000. The company recently disclosed preliminary U.S. fiscal year 2025 product revenues totaling $689 million, slightly under analyst expectations. This revenue outcome has resulted in contrasting brok…
James George Chopas, Vice President and Chief Accounting Officer at Apellis Pharmaceuticals, sold 726 shares to meet tax obligations linked to recently vested Restricted Stock Units. Apellis reported preliminary fiscal 2025 product revenues that did not meet certain analyst forecasts, eliciting a spectrum of analyst ratings ranging from Sell to Buy…
Nur Nicholson, the Chief Technical Officer at Apellis Pharmaceuticals, sold over 2,200 shares to fulfill tax withholding obligations related to recent restricted stock units. Meanwhile, Apellis disclosed preliminary U.S. fiscal 2025 product revenues that fell short of analyst expectations, triggering varied responses from financial institutions reg…
Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold over 2,200 shares in January 2026 to cover tax responsibilities. Concurrently, the company announced preliminary U.S. product revenue for fiscal year 2025 that fell slightly short of analyst expectations. Multiple analysts responded with varied ratings reflecting both positive pr…
Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, sold nearly 1,900 shares recently to satisfy tax liabilities tied to vested Restricted Stock Units. Concurrently, Apellis reported preliminary 2025 U.S. product revenue figures that surpassed $680 million but fell short of some Wall Street expectations, prompting varied analyst reac…
Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 1,882 shares of the company's stock to meet tax withholding duties tied to recently released Restricted Stock Units. The transaction took place against a backdrop of mixed fiscal year 2025 revenue results and varied analyst responses to Apellis’ market performance.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc., completed significant stock transactions on January 20, 2026, selling over $275,000 worth of shares while simultaneously exercising stock options. These moves occurred amid evolving analyst assessments and growing competition in the healthcare sector, particularly in the weight man…
On January 20, 2026, Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc., sold 9,067 shares of the company's Class A Common Stock for approximately $275,113, at an average price of $30.34 per share. Concurrently, he exercised options to acquire an equivalent number of shares at exercise prices of $5.01 and $11.53 respectively. These …
John D. Gottwald, one of Tredegar Corporation's major shareholders, sold a substantial block of company shares worth approximately $119,000 in mid-January 2026. This transaction occurs alongside a planned leadership change at Tredegar, with CEO John M. Steitz retiring at the year's end and Arijit DasGupta stepping in as his successor at the start o…
John D. Gottwald, a significant shareholder and ten-percent owner of Tredegar Corporation, recently sold approximately $119,000 worth of company shares. Concurrently, the company announced a planned CEO succession at the turn of the year, with Arijit DasGupta stepping into the leadership role as John M. Steitz plans his retirement. These developmen…
Manuel A. Diaz, a director at Outfront Media Inc, sold over 11,000 shares in a pre-arranged transaction, reducing his direct holdings. Meanwhile, leading financial institutions upgraded their outlook on the company, highlighting an improving U.S. advertising market and attractive valuation metrics. Outfront Media continues to engage actively in ind…
Manuel A. Diaz, a board director at Outfront Media Inc, recently sold over eleven thousand shares under a scheduled trading plan. Concurrently, major financial institutions have upgraded the stock, citing favorable market conditions. The company also continues active engagement in industry forums and innovative collaborations.
Sight Sciences CEO Paul Badawi sold over 22,000 shares of stock valued at approximately $148,000 on January 16, 2026. This insider transaction comes alongside the announcement of anticipated fourth-quarter revenue growth, favorable study results for their OMNI glaucoma device, and notable leadership shifts within the company.
UWM Holdings Corp’s CEO, Mat Ishbia, alongside SFS Holding Corp, collectively sold about 1.98 million shares of Class A Common Stock between January 16 and 21, 2026, raising approximately $11.1 million. Concurrently, UWM announced a mixed Q3 2025 financial performance surpassing revenue expectations but missing EPS targets. In a strategic developme…
